Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). “This was a safety-related labeling change for the glucagon-like peptide 1 receptor ...
The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
There's buzz around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant ...
Eli Lilly then sent cease-and-desist letters to many companies offering compounded versions of tirzepatide. Shortly after ...
The FDA is urging patients who have received drugs from Fullerton Wellness to stop using them and contact their health care provider.
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...
Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...
The U.S. Food and Drug Administration on Friday warned patients and health care professionals not to use compounded drugs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback